S100A8 and myocardial infarction: More importantly, short‐term ABR‐238901 treatment post‐myocardial infarction has been shown to inhibit inflammation and improve cardiac function,18, 19 indicating the potential of S100a8/a9 inhibitor as an immunomodulatory treatment of cardiotoxicity in cancer patients undergoing chemotherapy.